Complement 3 Glomerulopathy Pipeline Insight
DelveInsight’s, “Complement 3 Glomerulopathy – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Complement 3 Glomerulopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Complement 3 Glomerulopathy Understanding
Complement 3 Glomerulopathy: Overview
Complement 3 glomerulopathy (C3G) is a rare kidney disease that has two forms: dense deposit disease (DDD) and C3 glomerulonephritis (C3GN). Each is caused by genetic or acquired problems in controlling the body’s complement system, which helps fight infections. The ""C3"" refers to a blood protein that plays a key role in normal immunity and in the development of this disease. More on this later. The ""G"" is for glomerulopathy, meaning damage to the glomeruli in the kidney. Glomeruli filter your blood to get rid of toxins and make urine.
Common signs and symptoms of C3G are:
- Blood in the urine (hematuria)
- Excess protein in the urine (proteinuria)
- Reduced glomerular filtration rate (GFR; reduced ability of the kidney to filter the blood and make urine), elevated creatinine
- Swelling (edema) of hands, feet, ankles
- Urine test: A urine test will see if the patient have protein and blood in urine.
- Blood test: A blood test will tell if complement proteins are normal, and if wastes are building up in blood.
- Glomerular filtration rate (GFR): A blood test will be done to know how well kidneys are filtering the wastes from the body.
- Kidney biopsy: In this test, a tiny piece of your kidney is removed with a special needle, and looked at under special microscopes. The kidney biopsy may show lots of breakdown products of C3, without other proteins, in the glomeruli, which usually means C3G.
There is no FDA-approved treatment for C3G, nor are there therapies that attack the cause of C3G. Efforts to slow the process of kidney damage from C3G may include the following:
- Corticosteroids (often called steroids)
- Immunosuppressive drugs
- ACE inhibitors and ARBs
- Diet changes
- Complement inhibitors
- The companies and academics are working to assess challenges and seek opportunities that could influence Complement 3 Glomerulopathy R&D. The therapies under development are focused on novel approaches to treat/improve Complement 3 Glomerulopathy.
- In March 2017, the Food and Drug Administration granted orphan drug designation for avacopan in the treatment of patients with C3G.
- AMY-101 is the first drug to be granted an orphan drug status by the EMA and the US FDA for the indication of C3G.
Complement 3 Glomerulopathy Emerging Drugs Chapters
This segment of the Complement 3 Glomerulopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complement 3 Glomerulopathy Emerging Drugs
Narsoplimab: Omeros Corporation
Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. The lectin pathway is one of the principal pathways of complement and is activated primarily by tissue damage and microbial infection. Importantly, inhibition of MASP-2 does not appear to interfere with the classical complement pathway, a critical component of the acquired immune response to infection. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity. It is in phase II stage of development.
Avacopan is an orally-administered drug candidate that inhibits the complement C5a receptor, or C5aR, and is being developed for inflammatory and autoimmune diseases. Avacopan blocks the activity of complement C5a, a component of the complement system and the natural ligand for C5aR.
AMY-101: Amyndas Pharmaceuticals
AMY-101 is being developed by Amyndas Pharmaceuticals for the treatment of C3 Glomerulopathy. Its phase I trial is completed and phase II is planned.
Further product details are provided in the report……..
Complement 3 Glomerulopathy: Therapeutic Assessment
This segment of the report provides insights about the different Complement 3 Glomerulopathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Complement 3 Glomerulopathy
There are approx. 5+ key companies which are developing the therapies for Complement 3 Glomerulopathy. The companies which have their Complement 3 Glomerulopathy drug candidates in the most advanced stage, i.e. phase II include Omeros Corporation and others
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II )
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Complement 3 Glomerulopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Monoclonal antibodies
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Complement 3 Glomerulopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Complement 3 Glomerulopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Complement 3 Glomerulopathy drugs.
Complement 3 Glomerulopathy Report Insights
- Complement 3 Glomerulopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Complement 3 Glomerulopathy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Complement 3 Glomerulopathy drugs?
- How many Complement 3 Glomerulopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complement 3 Glomerulopathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Complement 3 Glomerulopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complement 3 Glomerulopathy and their status?
- What are the key designations that have been granted to the emerging drugs?